AstraZeneca is building an AI-and-robotics biologics lab to speed drug discovery
MIT Tech Review AI · rss · 2026-07-23
AstraZeneca says AI is now embedded across biologics R&D, with a build-measure-learn loop that ranks candidate molecules computationally and sends only the best ones to the lab.
- The company is building a “lab of the future” in Kendall Square, where AI, robotics, and instruments will form a closed-loop discovery system.
- Its proprietary multimodal datasets include molecular structures, binding measurements, safety profiles, and manufacturing outcomes, which it uses to fine-tune frontier models.
- AstraZeneca also points to virtual clinical trial-like systems — advanced cell models and micro-scale organ models — to improve safety prediction for de novo biologic design.
- The long-term goal is AI-generated proteins designed from scratch into clinical candidates, but the company says the field still needs better standardized data, benchmarks, and hybrid ML-biology talent.
- Sapra argues the hardest open problem is safety prediction for molecules generated computationally.
More from Companies & People
- Lumara AI Film Festival Comes to NYC Oct 26, Top AI Filmmakers to Compete — 0xAllen_ · 2026-09-11
- X drama: Anthropic researchers accused of spying on academic customers and racing them to results — basedjensen · 2026-09-11
- Investor argues Palantir-Nvidia partnership should slash Anthropic's IPO valuation — pdamodaran · 2026-09-11
- a16z podcast: why 2-3 person startups are absent from policy debates — a16z Podcast · 2026-09-11
- PyTorch Day Korea 2026 launches first offline conf, CFP closes Sept 13 — PyTorch · 2026-09-11
- Class action accuses Anthropic of overselling Claude subscriptions with deceptive usage multipliers — The Decoder · 2026-09-11